Fierce Healthcare
DECEMBER 14, 2021
Health systems reap big rewards by acquiring practices, but physicians aren’t sharing in those benefits, study finds. hlandi. Tue, 12/14/2021 - 12:46.
pharmaphorum
DECEMBER 14, 2021
Novartis as opted out of a collaboration with Mesoblast to develop its stem cell-based therapy remestemcel-L as a treatment for COVID-19, prompting a slump in the biotech’s share price. Novartis agreed to pay $25 million upfront for opt-in rights to remestemcel-L just over a year ago and to make a $25 million equity stake in Mesoblast, with up to $1.25 billion in additional payments tied to regulatory and commercial objectives.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Healthcare
DECEMBER 14, 2021
HHS to distribute $9B in COVID-19 relief funds to smaller providers this week. rking. Tue, 12/14/2021 - 11:31.
pharmaphorum
DECEMBER 14, 2021
Gilead Sciences has taken a big step towards positioning its CAR-T therapy Yescarta as an option for previously-untreated large B cell lymphoma (LBCL) with updated results from the ZUMA-12 trial at the ASH congress this week. The phase 2 trial showed that 78% of high-risk LBCL patients treated first-line with Yescarta (axicabtagene ciloleucel) had a complete response to the treatment after a follow-up period of just under 16 months, with an overall response rate of 89%.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Outsourcing Pharma
DECEMBER 14, 2021
Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.
pharmaphorum
DECEMBER 14, 2021
Pfizer has found another use for the windfall profits it is making from it BioNTech-partnered COVID-19 vaccine, agreeing to buy Arena Pharma and its late-stage ulcerative colitis drug etrasimod. The $100-per-share deal values Arena at around $6.7 billion, and gives Pfizer an entry into the oral S1P receptor modulator category that puts it in contention with Bristol-Myers Squibb and its already approved rival Zeposia (ozanimod).
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
DECEMBER 14, 2021
Embracing a “once-in-a-generation opportunity” to improve access to oncology treatments could save thousands of years of life across the European Union. Without “decisive action” cancer deaths across the European Union (EU) will increase by almost a quarter by 2035, making it the bloc’s leading cause of death. Expediating access to new treatments is key to avoiding this devastating outcome, according to a new publication from the European Federation of Pharmaceutical Industries and Associations
Fierce Healthcare
DECEMBER 14, 2021
U.K. antitrust watchdog investigates Microsoft-Nuance deal following E.U. probe. rtorrence. Tue, 12/14/2021 - 18:22.
pharmaphorum
DECEMBER 14, 2021
Data from a real-world study South Africa has indicated that the Omicron variant of COVID-19 is 29% less likely to cause hospitalisation among infected adults than other strains – although the researchers behind the work stress the findings are preliminary. The results – released by healthcare insurance group Discovery SA and the South African Medical Research Council – back up speculation among experts that Omicron may be less virulent than other variants even though it seems to have a frighten
Fierce Healthcare
DECEMBER 14, 2021
Supreme Court blocks challenge to New York's health worker vaccine mandate. hlandi. Tue, 12/14/2021 - 20:16.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Outsourcing Pharma
DECEMBER 14, 2021
According to the company, the latest Phase II/III study results show its novel oral treatment candidate is effective in reducing hospitalizations and deaths.
Fierce Healthcare
DECEMBER 14, 2021
Remote care management startup Cadence hits $1B valuation with $100M series B. rtorrence. Tue, 12/14/2021 - 15:02.
Turnkey Pharmacy Solutions
DECEMBER 14, 2021
Written By: Rich Bucher While implementing a referral capture strategy can potentially lead to significant 340B savings for your 340B covered entity (CE), it is important to remember that you, the CE, remain responsible for ensuring full compliance. Managing a fully compliant and cost-effective referral process will require diligence and resources, despite what some third-party.
pharmaphorum
DECEMBER 14, 2021
Digital health startup Cadence has reached a heady $1 billion valuation just a few months after launch, thanks to a $100 million financing. The latest round, led by Coatue Management, comes just four months after Cadence came out of stealth mode with $41 million in backing for its remote care management platform that allows doctors to monitor patients at home and engage with them via video consultations and messaging services.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
DECEMBER 14, 2021
Centene CEO Neidorff to retire next year. pminemyer. Tue, 12/14/2021 - 10:37.
pharmaphorum
DECEMBER 14, 2021
Define-XML is the metadata that describes the content and formatting of submission datasets and the case report tabulation data. It’s needed to help reviewers understand the data they are reviewing. It’s based on the CDISC ODM standard and is a key requirement for electronic submissions to the FDA and PDMA. Creating a Define-XML requires a lot of programming expertise.
Pharma Times
DECEMBER 14, 2021
Nivolumab plus ipilmumab has been accepted as a treatment option for adult patients by NHS Scotland for patients who have previously failed fluoropyrimidine-based chemotherapy.
pharmaphorum
DECEMBER 14, 2021
Australian biotech group CSL has agreed a deal to acquire Swiss drugmaker Vifor Pharma in an all-cash deal that expands its speciality medicines business. If it goes through, the merger will allow CSL to diversify its business which is focused mainly on plasma-derived medicines sold by its CSL Behring unit and vaccines under the Seqirus arm, adding drugs for iron deficiency and cardio-renal disease that brought in sales of $1.85 billion last year.
Pharma Times
DECEMBER 14, 2021
The public have been assured more sites, mobile units and pop-ups would be set up across the country to fulfill the vaccination pledge ahead of the original deadline of 31 January 2022.
Roots Analysis
DECEMBER 14, 2021
Innovators in the pharmaceutical industry are constantly developing ways to improve the process of conducting clinical trials and managing research sites. Amidst other alternatives, outsourcing various trial operations to a specialized service provider, such as site management organizations (SMOs), has emerged as a viable option for various developers.
Fierce Healthcare
DECEMBER 14, 2021
Senators press Biden administration to clamp down on insurers flouting ACA birth control cost-sharing rules. rking. Tue, 12/14/2021 - 15:41.
Expert insights. Personalized for you.
118 
Let's personalize your content